Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512575 | 0.87 | CTSS (0.42) | GRM2PRKDCCTSS | |
| SCHEMBL8510782 | 0.87 | GRM2 (0.37) | GRM2F2MRGPRX4 | |
| SCHEMBL8511759 | 0.87 | GRM2 (0.37) | GRM2F2CTSSNPC1MAPT | |
| SCHEMBL8510239 | 0.85 | F2RL3 (0.39) | GRM2PDCD1CD274CTSS | |
| SCHEMBL8511915 | 0.85 | F2RL3 (0.39) | GRM2CTSSMAPT | |
| SCHEMBL8512353 | 0.84 | GRM2 (0.38) | GRM2F2MRGPRX4 | |
| SCHEMBL9604222 | 0.84 | GRM2 (0.42) | GRM2F2MAPTMRGPRX4 | |
| SCHEMBL8510140 | 0.82 | GRM2 (0.37) | GRM2CTSSMRGPRX4 | |
| SCHEMBL8511776 | 0.82 | GRM2 (0.33) | GRM2CTSSMRGPRX4 | |
| SCHEMBL8510325 | 0.80 | GRM2 (0.35) | GRM2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | GRM2 1/4885PRKDC 4385/4885PDCD1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.